PMID: 6983149Jan 1, 1981Paper

Clone size potential and sensitivity to colony-stimulating activity: differentiation-linked properties of granulocyte-macrophage progenitor cells

Stem Cells
G E FrancisA V Hoffbrand

Abstract

Previous studies using semi-solid agar cultures of acute myeloid leukaemia (AML) cells have shown that proliferative capacity (clone size potential) and the degree of sensitivity of clone-forming cells to the specific granulocyte-macrophage regulatory colony-stimulating activity (CSA) are closely linked AML cell properties. The purpose of this study was to determine whether this association is confined to AML cells or whether the linking of these two properties in AML represents retention of an association occurring in normal granulocyte-monocyte progenitor cell populations. Bone marrow cells from normal donors were studied using four independent techniques to enrich for clonogenic cells with different clone size potentials (equilibrium density centrifugation, adherence to microcarrier beads, osmotic lysis and fluorescence-activated cell sorting). It was shown that mean clone size was directly related to the mean CSA threshold (amount of CSA required to stimulate 50% of the cells to clone formation). Further studies (including analysis of the kinetics of production of clonogenic cells with different clone size potentials in suspension culture) suggested that these two properties were linked to differentiation, with proliferativ...Continue Reading

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.